Browsing by Title
Now showing items 15155-15174 of 24743
-
Article
P -wave ππ scattering and the ρ resonance from lattice QCD
(2017)We calculate the parameters describing elastic I=1, P-wave ππ scattering using lattice QCD with 2+1 flavors of clover fermions. Our calculation is performed with a pion mass of mπ≈320 MeV and a lattice size of L≈3.6 fm. ...
-
Article
-
Conference Object
-
Article
p-Hydroquinone-metal compounds: Synthesis and crystal structure of two novel VV-p-hydroquinonate and VIV-p-semiquinonate species
(2002)Reaction of the p-hydroquinone derivative H2Na4bicah·4H2O with either VIVOSO4·3H2O and NaVVO3 in equivalent quantities or with NaVVO3 yields the tetranuclear VIVO2+ macrocycle-semiquinonate compound Na6{(VIVO)4-(μ2-O) ...
-
Article
p-phenylenecarbenonitrene and its halogen derivatives: How does resonance interaction between a nitrene and a carbene center affect the overall electronic configuration?
(2001)A series of para-conjugatively coupled phenylenecarbenonitrenes {(4-nitrenophenyl)methylene (3a), (4-nitrenophenyl)fluoromethylene (3b), (4-nitrenophenyl)chloromethylene (3c), and (4-nitrenophenyl)bromomethylene (3d)} were ...
-
Doctoral Thesis Open Access
P-type half-Heusler and Bismuth-Telluride thermoelectric materials
(Πανεπιστήμιο Κύπρου, Πολυτεχνική Σχολή / University of Cyprus, Faculty of Engineering, 2022-05)Την τελευταία δεκαετία τα θερμοηλεκτρικά υλικά τύπου half-Heusler of (MCoSb και MNiSn (M = Ti, Zr, Hf)) έχουν κινήσει το επιστημονικό ενδιαφέρον για εφαρμογές μεσαίων και υψηλών θερμοκρασιών λόγω των υποσχόμενων ...
-
Article
A p-version MITC finite element method for Reissner-Mindlin plates with curved boundaries
(2006)We consider the approximation of Reissner-Mindlin plates with curved boundaries, using a p-version MITC finite element method. We describe in detail the formulation and implementation of the method, and emphasize the need ...
-
Article Open Access
P. Oxy. LXXI 4808: bios, character, and literary criticism
(Rudolf Habelt Verlag GMBH, 2015)This paper discusses the literary genre of the unknown prose text published in volume LXXI of the Oxyrhynchus Papyri by A. G. Beresford, P. J. Parsons, and M. P. Pobjoy.
-
Article
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
(2009)The reprogramming of differentiated cells to pluripotent cells (induced pluripotent stem (iPS) cells) is known to be an inefficient process. We recently reported that cells with short telomeres cannot be reprogrammed to ...
-
Article
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
(1998)The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...
-
Article
-
Article
-
Article
Packet scheduling over a wireless channel: AQT-based constrained jamming
(2015)In this paper we consider a two-node setting with a sender transmitting packets to a receiver over a wireless channel. Unfortunately, the channel can be jammed, thus corrupting the packet that is being transmitted at the ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
(2000)Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study
(1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
(1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
(2005)Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...
-
Article
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
(1997)Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using ...
-
Article
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
(1999)Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
(2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...